HPV相关原发不明鳞癌与早期口咽癌的配对比较
单中心回顾性队列匹配分析比较T0N1-3M0 HPV阳性原发不明癌(CUP)与T1-2N1-3M0 HPV阳性口咽癌(OPX)的生存结局。
要点
- T0N+M0 HPV相关CUP与匹配的早期口咽癌生存相似
- CUP可参照早期口咽癌进行风险分层并纳入降阶治疗试验
- CUP中HPV状态未知者可经推算纳入分析
核心结论
- T0N+M0 HPV诱导的CUP与匹配的T1-2N+M0 HPV+口咽癌生存结局相似。
- 此类CUP患者可合理纳入降阶治疗临床试验并按早期口咽癌风险分层。
研究设计与样本
- 单中心1998至2016年接受根治性治疗的早期T分期、淋巴结阳性HPV+口咽癌或CUP患者的回顾性队列研究。
- 298例T1-2N1-3口咽癌患者中48例与48例HPV+ CUP患者匹配,CUP中32例HPV状态确认、16例推算。
- 采用最近邻倾向性技术按人口学特征匹配,并按当前NRG Oncology试验入组标准分为有利或不利风险分层。
关键数值与推荐
- HPV状态未知的CUP患者按HPV+概率>80%推算纳入。
临床怎么用
- T0N+M0 HPV相关CUP可按早期口咽癌同等对待进行风险分层。
- 可考虑将此类患者纳入降阶治疗临床试验。
局限性
- 单中心回顾性研究,证据等级为4级。
- 部分CUP患者HPV状态为推算而非确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Patients with human papillomavirus (HPV)-induced cancer of unknown primary (CUP) are generally excluded from clinical trials, despite surgical series reporting detection rates of occult oropharynx primaries of >80%. We performed a matched-pair analysis to compare outcomes between T0N1-3M0 HPV+ CUP and T1-2N1-3M0 HPV+ oropharynx known primary (OPX). STUDY DESIGN: Retrospective cohort study at a single institution. METHODS: Patients with early T stage, node positive HPV+ OPX or CUP treated with curative intent between 1998 and 2016 were identified. For a subgroup of CUP patients with an unknown HPV status, we imputed HPV status and included patients with a >80% probability of being HPV+. Cohorts were matched based on patient demographics using a nearest neighbor propensity technique. After matching, patients were grouped according to either a favorable or unfavorable risk stratification designations per current NRG Oncology clinical trial enrollment criteria. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan-Meier analysis. RESULTS: Of 298 patients with T1-2N1-3 OPX, 48 were matched to 48 HPV+ CUP patients (32 with confirmed and 16 imputed HPV status). Median follow-up for CUP (34.1 months) and OPX (27.8 months) patients were similar (P = .23).There were no significant differences between the CUP and OPX groups for 3-year DFS (89% vs. 85%, P = .44), and 3-year OS (91% vs. 91%, P = .11), respectively. CONCLUSIONS: Patients with T0N+M0 HPV-induced CUP have similar survival outcomes to matched patients with T1-2N+M0 HPV+ OPX. These patients can reasonably be included in clinical trials investigating the role of treatment deintensification and risk stratified similar to patients with early-stage known primary OPX cancer. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:1379-1385, 2018.
引用
- Ross RB, Koyfman SA, Reddy CA, et al. A matched comparison of human papillomavirus-induced squamous cancer of unknown primary with early oropharynx cancer. Laryngoscope. 2017. PMID: 29086413. doi:10.1002/lary.26965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。